What Is the Treatment of Gastrointestinal Anthrax?
Gastrointestinal anthrax is a severe form of anthrax infection requiring prompt, structured antibiotic management. Therapeutic decisions are guided by local pathogen susceptibility data and the patient's clinical presentation.
Treatment Approach
The first-line strategy is empiric combination antibiotic therapy with two agents — the specific agents selected based on local penicillin susceptibility patterns and the clinical context. Full agent selection, dosing, and algorithm available in the complete protocol below.
Treatment Goals
The aim is to achieve clear, documented clinical improvement and confirmed clinical stability before therapy is discontinued. A minimum treatment duration applies, extended further when stability has not yet been reached.
References
DOI: 10.2471/B09539.
- In the presence of any of these scenarios, empiric combination therapy with two antibiotics is recommended.
- The first agent should be selected from ciprofloxacin, ampicillin, or penicillin G, based on local penicillin susceptibility patterns (Table 4).
- The second agent should be chosen according to the clinical presentation: intravenous clindamycin for inhalation or injection-related anthrax, oral clindamycin for severe cutaneous anthrax, or intravenous gentamicin for gastrointestinal anthrax.
- Overall, treatment duration should be extended for at least 14 days or until the patient is clinically stable, whichever is longer.
- Clear clinical improvement should always be documented prior to therapy discontinuation.
View source ↗